GRTS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRTS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Gritstone Bio's enterprise value is $110.62 Mil. Gritstone Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.33 Mil. Therefore, Gritstone Bio's EV-to-Revenue for today is 83.05.
The historical rank and industry rank for Gritstone Bio's EV-to-Revenue or its related term are showing as below:
During the past 8 years, the highest EV-to-Revenue of Gritstone Bio was 1906.37. The lowest was 1.11. And the median was 33.68.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-01), Gritstone Bio's stock price is $0.8737. Gritstone Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Gritstone Bio's PS Ratio for today is 79.43.
The historical data trend for Gritstone Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gritstone Bio Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 50.77 | 11.96 | 15.26 | 18.15 | 168.73 |
Gritstone Bio Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 18.15 | 29.05 | 58.68 | 65.19 | 168.73 |
For the Biotechnology subindustry, Gritstone Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Gritstone Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Gritstone Bio's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Gritstone Bio's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 110.620 | / | 1.332 | |
= | 83.05 |
Gritstone Bio's current Enterprise Value is $110.62 Mil.
Gritstone Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gritstone Bio (NAS:GRTS) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Gritstone Bio's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.8737 | / | 0.011 | |
= | 79.43 |
Gritstone Bio's share price for today is $0.8737.
Gritstone Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Gritstone Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lawrence Corey | director | C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Naiyer Rizvi | director | C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Elaine V Jones | director | C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101 |
Clare Fisher | director | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Steve E. Krognes | director | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Shefali Agarwal | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Vassiliki Economides | officer: See Remarks | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Erin Jones | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
James Cho | officer: Chief Accounting Officer | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Raphael Rousseau | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Roman Yelensky | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Thomas Woiwode | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Rahsaan Thompson | officer: EVP and General Counsel | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Vijay Yabannavar | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Nicholas Simon | director | 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142 |
From GuruFocus
By GlobeNewswire • 08-16-2023
By sperokesalga sperokesalga • 06-01-2023
By Value_Insider Value_Insider • 12-15-2022
By sperokesalga sperokesalga • 05-03-2023
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 10-11-2023
By Marketwired • 10-04-2023
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 09-05-2023
By Stock market mentor Stock market mentor • 01-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.